Evidence map›Paper›PMID 39514948›Full record

ArticleMolecular immunology2024

Preclinical assessment of the efficacy of B7-H3 CAR-T in renal cell carcinoma.

Huizhong Li, Fei Wang, Haifang Zhao, Jiale Cao, Shiyuan Wang, Hongxia Li, Barbara Savoldo, Enyu Rao, Gianpietro Dotti, Hongwei Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huizhong LiCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Fei WangCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Haifang ZhaoCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Jiale CaoCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Shiyuan WangCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Hongxia LiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101125, China.
Barbara SavoldoLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599, USA.
Enyu RaoCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
Gianpietro DottiLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: gdotti@med.unc.edu.
Hongwei DuCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China. Electronic address: hwdu@xzhmu.edu.cn.

Funding

Targeting B7-H3 in ovarian cancerR01CA256898 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gianpietro Dotti, Linda Van Le · 2021 to 2026
$3.1M
Targeting the Ig-light chains with CAR-T cells in lymphoid tumorsR01CA193140 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOTTI, GIANPIETRO · 2016 to 2020
$2.7M
Tuning CAR-T cell functionR01CA247436 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOTTI, GIANPIETRO · 2021 to 2025
$2.4M
Cellular Immunotherapy of Ovarian CancerR01CA243543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOTTI, GIANPIETRO · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA193140NCI NIH HHS R01 CA243543NCI NIH HHS R01 CA247436NCI NIH HHS R01 CA256898
6 · The paper itself

Abstract

B7-H3 is a type I transmembrane protein that belongs to the B7 immune checkpoint protein family, is aberrantly expressed in cancer cells, but rarely expressed in normal tissues, making it an attractive target for cancer therapy. Here, we found B7-H3 is highly expressed in the renal cell carcinoma (RCC) tumor tissues and RCC cell lines, but is undetectable in normal renal tissues. Therefore, we engineered second-generation CAR-T cells targeting B7-H3, incorporating either CD28 or 4-1BB co-stimulatory domains. Both CAR-T cell variants demonstrated potent antitumor activity against RCC tumors in vitro and in metastatic and orthotopic RCC mouse models. Furthermore, the B7-H3 CAR-T cells exhibited remarkable proliferation and robust cytokine release when co-cultured with RCC cancer cells. These findings demonstrated that targeting B7-H3 by CAR-T cells potentially offering a new treatment option for RCC patients.

Indexed as

B7 AntigensCarcinoma, Renal CellImmunotherapy, AdoptiveKidney NeoplasmsReceptors, Chimeric AntigenAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceT-LymphocytesXenograft Model Antitumor AssaysB7 AntigensCD276 protein, humanReceptors, Chimeric AntigenB7-H3CAR-TRenal cell carcinoma

Identifiers

PMID39514948
PMCPMC11631664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.